Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 24Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 16Urinary Bladder Neoplasms 12Cholangiocarcinoma 12Breast Neoplasms 10Biliary Tract Neoplasms 10Neoplasms 9Neoplasm Metastasis 9Liver Neoplasms 9Pancreatic Neoplasms 7Carcinoma 6Endometrial Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Stomach Neoplasms 3Respiratory Tract Neoplasms 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Thyroid Neoplasms 2Thoracic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

Carboplatin 6Radiotherapy 5Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Pemetrexed 3Biopsy 3Bevacizumab 3capmatinib 2Radiotherapy, Conformal 2Platinum 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1osimertinib 1methoxyamine 1lazertinib 1fludarabine phosphate 1durvalumab 1defactinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × durvalumab × 90 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡